The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Fish Oil, DASH Diet Partially Alters Lipid Metabolism in Patients with Type 2 Diabetes
Fish oil intervention and DASH diet show no statistically significant effect on glycemic control and adiposity.
Bisphenol-A Linked to Insulin Resistance in Diabetic Patients
Participants with diabetes mellitus specifically were more prone to develop insulin resistance due to BPA exposure as compared to non-diabetic participants
Sortilin 1 Gene Shows Positive Association with Coronary Artery Disease
Data show the relative expression of SORT1 gene was upregulated by 4.438 fold in patients with CAD, compared to control.
New Study Details PWT2D Experiences with Basal Insulin Titration
Of the 416 basal insulin initiators, only one-third of them reached the appropriate fasting blood glucose level.
Phil Zeitler, MD: Risk Factor Development in Youth-Onset Type 2 Diabetes
Dr. Zeitler highlights the long-term microvascular risk complications observed in T2D patients in the TODAY2 observational study.
Greater Reductions in HbA1c in Insulin-Naïve PW2D Treated with Gla-300
These reductions, investigators noted, were slightly greatest yet not statistically significant.
Arterial Stiffness Bidirectionally Associated with General, Central Adiposity in Adolescents
Data show cfPWV at 17.7 years was independently and directly associated with total fat mass and trunk fat mass at 24.5 years.
Adipocytokines, Oxidized LDL Aid in Metabolic Balance in Hypertensive Patients.
Investigators added that they interact directly with the insulin signal transmission pathways.
Complete Revascularization in ACS Patients Related to Cardiorespiratory Fitness
Investigators also reported that cardiorespiratory fitness was superior in patients with complete revascularization when compared to the patients with incomplete revascularization.
Triple Therapy In T2D Care Linked To Lower Rate Of Hepatic Steatosis, Fibrosis
Patients with type 2 diabetes treated with triple therapy had less hepatic steatosis and fibrosis and significantly improved insulin sensitivity versus conventional therapy.
Investigators Confirm Efficacy of Dasiglucagon for Treatment of Hypoglycemia
The team estimated the time to individual plasma glucose recovery following exposure to the medication.
Hyperinsulinemia Rates in US Adults Significantly Increased Over 20 Year Period
Data show the age-adjusted prevalence of hyperinsulinemia in adults without diabetes increased by 18% in the study population between 1999 - 2000 and 2017 - 2018.
Severe COVID-19 Symptoms Recorded in Patients with Nonalcoholic Fatty Liver Disease
In keeping with earlier data, investigators suggested that metabolic syndrome was associated with severe cases of infection.
José-Alain Sahel, MD: Safety, Efficacy of Optogenetic Treatment for Retinitis Pigmentosa
At AAO 2021, Dr. Sahel discussed the findings of the PIONEER trial on the combination of an optogenetics device and gene therapy in treatment of RP.
Robert L. Avery, MD Highlights Results on RGX-314 For the Treatment Of Wet AMD
Dr. Avery discusses the positive results of RGX-314 gene therapy, noting dramatic reduction in need for therapy, with stable vision and good thickness results
Dilsher S. Dhoot, MD: Efficacy of Brolucizumab in Treatment of Diabetic Macular Edema
Dr. Dhoot discusses data on visual acuity from the phase 3 KESTREL and KITE trials, comparing brolucizumab to aflibercept at 52 weeks.
Abrocitinib Dosing Effective in Atopic Dermatitis Management
Investigators said that patient-reported outcomes from the 2 abrocitinib groups showed greater efficacy than the dupilumab and placebo groups.
Study Evaluates Sun Protection Awareness in Adolescents
Respondents suggested that increasing product availability and demonstrating the consequences of sunburn could increase sun protection among young people.
Arshad Khanani, MD Discusses Adverse Ocular Events After Brolucizumab Treatment
Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.
Veeral Sheth, MD: Identifying Durability, Safety of GB-102 in Wet AMD Treatment
Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.
Boni Elewski, MD: Biologics for Pediatric Psoriasis Patients
Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.
Lisa Swanson, MD: Detailing Infantile Hemangioma
Though not all hemangioma last past 10 years old in pediatric patients, some untreated hemangioma are associated with high risk of ulceration.
Saakshi Khattri,MD: Evolving Therapies for Psoriatic Disease
Though Dr. Khattri felt the diagnosis of psoriatic arthritis had been “stagnant”, the inclusion of biologic therapies and more has been a welcomed change.
Boni Elewski, MD: Safety and Efficacy of New Psoriasis Therapies
Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.
Lisa Swanson, MD: The Psychology of Pediatric Chronic Skin Conditions
Dr. Swanson also details the effects of the COVID-19 pandemic on her practice with the implementation of telemedicine.
Seemal Desai, MD: The Promise of JAK Inhibitors in Vitiligo Management
Dr. Desai says that Janus kinase inhibitors present a new mechanism of action, with effects on cytokine signals that signal inflammation in atopic diseases.
Boni Elewski, MD: The Future of Psoriasis Therapy
Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.
Lisa Swanson, MD: Detailing Therapies for Pediatric Skin Conditions
Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.
Saakshi Khattri, MD: Diagnosing Psoriatic Arthritis Early in Psoriasis Patients
Dr. Khattri speaks of the benefits of diagnosing the condition early in psoriasis patients, as well as what dermatologists can do before referring a patient to a rheumatologist.
Seemal Desai, MD: Advancements in Vitiligo Therapies
New therapies are breaking ground in the world of vitiligo research, which Dr. Desai believes will result in FDA approvals in the coming years.